Article
Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
Annals of internal medicine - 20 Jan 2009
Eckman Mark H, Rosand Jonathan, Greenberg Steven M, Gage Brian F
Abstract excerpt
BACKGROUND: Variants in genes involved in warfarin metabolism and sensitivity affect individual warfarin requirements and the risk for bleeding. Testing for these variant alleles might allow more personalized dosing of warfarin during the induction phase. In 2007, the U.S. Food and Drug Administration changed the labeling for warfarin (Coumadin, Bristol-Myers Squibb, Princeton, New Jersey), suggesting that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.